Research programme : alpha-1A adrenergic antagonists - SOM Biotech

Drug Profile

Research programme : alpha-1A adrenergic antagonists - SOM Biotech

Alternative Names: Benign prostatic hyperplasia therapeutics - SOM Biotech; SOM2391; SOM2393

Latest Information Update: 27 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SOM Biotech
  • Class
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Benign prostatic hyperplasia

Most Recent Events

  • 12 Apr 2016 Research programme : alpha-1A adrenergic antagonists - SOM Biotech is available for licensing as of 12 Apr 2016.
  • 12 Apr 2016 Preclinical trials in Benign prostatic hyperplasia in Spain (unspecified route) prior to April 2016 (SOM Biotech's pipeline, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top